Literature DB >> 6120349

Histological evidence of hepatitis-B-virus infection with negative serology in children with acute leukaemia who develop chronic liver disease.

D Vergani, A Locasciulli, G Masera, A Alberti, G Moroni, D E Tee, B Portmann, G Mieli Vergani, A L Eddleston.   

Abstract

A high percentage of patients with acute leukaemia in established remission develop chronic liver disease: how important hepatitis-B-virus (HBV) infection is as an aetiological factor is not clear. The presence of HBV markers in liver and serum of 23 leukaemic children with liver disease was investigated at the time of a diagnostic biopsy just before treatment withdrawal. Although, at this time, none had HBV antigens or antibodies in the serum by radioimmunoassay, HBsAg was detected by direct immunofluorescence in the cytoplasm of hepatocytes in 13 children, 7 of whom also had hepatitis-B core or e antigens in hepatocyte nuclei. This pattern of both cytoplasmic and nuclear fluorescence was present in 4 of 6 patients with the histological features of chronic active hepatitis on liver biopsy. The failure of release of viral antigens into serum and the absence of an adequate immune response were probably due to the intense chemotherapy used to induce and maintain remission, since HBV markers appeared in the serum within 15 months of stopping treatment in 8 of the children in whom viral antigens had been detected in liver tissue but in none of those whose biopsy specimens were negative by immunofluorescence. These results suggest that HBV infection may be an important cause of chronic liver disease in children with leukaemia and show that during treatment serological tests may fail to detect the presence of the virus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6120349     DOI: 10.1016/s0140-6736(82)91392-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Dissociation of alanine aminotransferase values in acute hepatitis A patients with and without past experience to the hepatitis B virus.

Authors:  A A Papachristou; A S Dumas; V C Katsouyannopoulos
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

2.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

3.  Clinical and biochemical reactivation of HBV infection in a thalassemic patient after bone marrow transplantation.

Authors:  S Li Volti; G Pizzarelli; M Galimberti; F Di Gregorio; M A Romeo; G Lucarelli; G Russo
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

4.  Presence of hepatitis B virus DNA in serum of surface-antigen-seronegative immunocompromised patients.

Authors:  C C Pao; W L Yang; S Y Wu; G M Lai; L Y Shih; C F Sun; Y F Liaw
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

5.  Importance of showing HBsAg and HBcAg positivity in the liver for better aetiological definition of chronic liver disease.

Authors:  L Cuccurullo; M Rambaldi; G Iaquinto; F Ferraraccio; L Ambrosone; N Giardullo; A De Vita
Journal:  J Clin Pathol       Date:  1987-02       Impact factor: 3.411

6.  Detection of hepatitis B virus pre-S1 and pre-S2 determinants in paraffin wax embedded liver tissue: importance of reagents used.

Authors:  N Hadzic; A Alberti; B Portmann; D Vergani
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

7.  Frequency of hepatic HBV-DNA in patients with cirrhosis and hepatocellular carcinoma: relation to serum HBV markers.

Authors:  Y S White; P J Johnson; F Davison; R Williams
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

8.  Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report.

Authors:  Nicholas Brousseau; Donald G Murphy; Vladimir Gilca; Jacynthe Larouche; Sema Mandal; Richard S Tedder
Journal:  J Med Case Rep       Date:  2017-04-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.